Results 71 to 80 of about 4,071 (233)

Comparative Efficacy and Safety of Advanced Intravitreal Therapeutic Agents for Noninfectious Uveitis: A Systematic Review and Network Meta-Analysis

Frontiers in Pharmacology, 2022
Background: To compare the efficacy and safety of advanced intravitreal therapeutic regimens, including a dexamethasone implant at 350 and 700 μg; a fluocinolone acetonide (FA) implant, 0.2 µg/day, 0.59 and 2.1 mg; intravitreal bevacizumab, 1.25 mg ...
Weiting Liao, Zhenyu Zhong, Guannan Su, Xiaojie Feng, Peizeng Yang   +4 more
doaj   +1 more source

Prognostic biomarkers of chronic diabetic macular edema treated with a fluocinolone acetonide intravitreal implant [PDF]

, 2021
Background: This study aimed to investigate retinal imaging biomarkers, such as disorganization of the retinal inner layers (DRIL) and/or ellipsoid zone (EZ) disruption by spectral domain optical coherence tomography (SD-OCT), and functional outcomes in ...
Aerts , Florence, Brizido, Margarida Sena, Lopes, Beatriz Oliveira, Miranda, Margarida Isidoro, Pina, Susana Morais, Simoes, Pedro Santana   +5 more
core   +2 more sources

Predictors of Long-Term Visual Outcome in Intermediate Uveitis [PDF]

, 2017
PURPOSE: To describe factors that predict visual loss and complications in intermediate uveitis. DESIGN: Cross-sectional study. PARTICIPANTS: Subjects with intermediate uveitis were identified from a database of 1254 uveitis patients seen ...
Bar, A, Lightman, SL, Niederer, RL, Sharief, L, Tomkins-Netzer, O   +4 more
core   +1 more source

Anti-Inflammatory Effect of Dexamethasone Controlled Released From Anterior Suprachoroidal Polyurethane Implants on Endotoxin-Induced Uveitis in Rats. [PDF]

, 2016
Targeted drug delivery to the ocular tissues remains a challenge. Biodegradable intraocular implants allow prolonged controlled release of drugs directly into the eye. In this study, we evaluated an anterior suprachoroidal polyurethane implant containing
Ayres, E., Barbosa Saliba, J., Behar-Cohen, F., Bousquet, E., Fernandes-Cunha, G.M., Kowalczuk, L., Ligório Fialho, S., Naud, M.C., Oréfice, R.L., Rodrigues Da Silva, G., Silva-Cunha, A., Tekaya, M., Vieira, L., Zhao, M.   +13 more
core   +2 more sources

Fluocinolone Acetonide Ophthalmic ??? Bausch & Lomb

Drugs in R & D, 2005
Bausch & Lomb and Control Delivery Systems have developed an intravitreal implant that can deliver the corticosteroid fluocinolone acetonide [fluocinolone acetonide implant, Retisert] to posterior eye tissue for up to 3 years. The implant uses Bausch & Lomb's Envision TD technology.
openaire   +2 more sources

Therapeutic approaches with intravitreal injections in geographic atrophy secondary to age-related macular degeneration: current drugs and potential molecules [PDF]

, 2019
The present review focuses on recent clinical trials that analyze the efficacy of intravitreal therapeutic agents for the treatment of dry age-related macular degeneration (AMD), such as neuroprotective drugs, and complement inhibitors, also called ...
Cerini, Alberto, Greco A., La Cava M, Lambiase A, Limoli PG, Nebbioso M   +5 more
core   +1 more source

Intraocular Pressure in Patients With Uveitis Treated With Fluocinolone Acetonide Implants [PDF]

Archives of Ophthalmology, 2007
To report the incidence and management of elevated intraocular pressure (IOP) in patients with uveitis treated with the fluocinolone acetonide (FA) intravitreal implant.Pooled data from 3 multicenter, double-masked, randomized, controlled, phase 2b/3 clinical trials evaluating the safety and efficacy of the 0.59-mg or 2.1-mg FA intravitreal implant or ...
Debra A, Goldstein, David G, Godfrey, Anthony, Hall, David G, Callanan, Glenn J, Jaffe, P Andrew, Pearson, Dale W, Usner, Timothy L, Comstock   +7 more
openaire   +2 more sources

Changes in Ganglion Cell Layer Thickness after Treatment with the 0.2 µg/day Fluocinolone Acetonide Implant in Vitrectomized and Nonvitrectomized Eyes with Diabetic Macular Edema

Ophthalmic Research, 2022
Introduction: The objective of this study is to compare changes in ganglion cell layer (GCL) between vitrectomized and nonvitrectomized eyes with diabetic macular edema (DME) over a 2-year period following treatment with 0.2 µg/day fluocinolone acetonide
B. Pessoa, C. Castro, André Ferreira, João Leite, João Heitor, P. Menéres, J. Figueira, A. Meireles, J. Beirão   +8 more
semanticscholar   +1 more source

Treatment of steroid-induced elevated intraocular pressure with anecortave acetate: a randomized clinical trial. [PDF]

, 2012
PURPOSE: The present study is the first randomized clinical trial designed to evaluate the intraocular pressure (IOP)-lowering effect of anecortave acetate (AA) administered at 3 doses (3, 15, or 30 mg) as an anterior juxtascleral depot (AJD) in patients
Bergamini, Michael V. W., Callanan, David G., Dickerson, Jaime E., Dirks, Monte S., Landry, Theresa A., Moster, Marlene R., Robin, Alan L., Scheib, Sally A., Stalmans, Ingeborg, Van Calster, Joachim   +9 more
core   +2 more sources

Smart Biomaterials and Dressings for the Treatment of Chronic Inflammatory Skin Diseases

Rare Metals, EarlyView.
ABSTRACT Chronic inflammatory skin diseases, encompassing immune‐inflammatory conditions and infection‐associated dermatoses, pose significant clinical challenges due to high prevalence, recurrence, and therapeutic resistance, affect over 30% of the global population.
Zehao Lan, Shengjie Xue, Junyi Yin, Shaolei Wang, Yunlei Zhou, Jieyue Liao   +5 more
wiley   +1 more source